Search Patents
  • SYSTEMS, METHODS AND COMPOSITIONS FOR EFFECTIVE SANITIZING OR DISINFECTING
    Publication number: 20210290508
    Abstract: Apparatus and methods for producing a sanitizing composition are described. The apparatus includes: (1) one or more first reactors for heating alcohol with a cannabidiol (“CBD”) and/or a cannabigerol (CBG) to produce an intermediate sanitizing composition; and (2) a first homogenizing subsystem including a first homogenizing blade for mixing alcohol with the intermediate sanitizing composition to produce a first homogenized composition. Methods of the present teachings include: (1) mixing alcohol with a CBD and/or a CBG to produce an intermediate sanitizing composition; (2) cooling the intermediate sanitizing composition to a temperature that ranges from about 10° C. to about 30° C. to produce a cooled intermediate sanitizing composition; and (3) admixing the cooled intermediate sanitizing composition with an alcohol and water solution to produce the sanitizing composition.
    Type: Application
    Filed: March 23, 2021
    Publication date: September 23, 2021
    Applicant: Soulshine Development Group, Inc.
    Inventors: Patrick J. Wlaznak, Robert William LaChance, II
  • INCLUSION COMPOUND CONTAINING NON-PSYCHOACTIVE CANNABINOID AND METHOD FOR PREPARTION THEREOF
    Publication number: 20220218624
    Abstract: Disclosed are an inclusion compound containing a non-psychoactive cannabinoid, and a method for preparation thereof. The inclusion compound is prepared by means of the following method: a cannabis extract is subjected to, in sequence, dissolving in organic solvent, incorporation of inclusion agent, analysis and removal of impurities in water-organic solvent, and vacuum drying and precipitation, and thus obtained. In the inclusion compound, psychoactive ingredients such as tetrahydrocannabidiol (THC) and ?9-tetrahydrocannabinol (THCV) may be completely removed, effectively enriching the non-psychoactive ingredients such as cannabidiol (CBD), cannabigerol (CBG), cannabichromene (CBC), and so on with a total content of greater than 50%. The processing technique of the preparation method is simple to perform, and is conducive to commercialization.
    Type: Application
    Filed: May 14, 2020
    Publication date: July 14, 2022
    Applicant: HANYI BIO-TECHNOLOGY (BEIJING) CO., LTD.
    Inventors: Wuxing SUN, Xin TAN, Jing ZHANG, Qian JIN, Shubin WANG, Junbo XING
  • METHODS OF SYNTHESIZING CANNABIGERGOL, CANNABIGEROLIC ACID, AND ANALOGS THEREOF
    Publication number: 20220281790
    Abstract: Disclosed are methods for preparing cannabigerol (CBG) or a CBG analog, embodiments of the method comprising providing a compound (I); combining the compound (I) with geraniol and a solvent to form a reaction mixture; and combining the reaction mixture with an acid catalyst to form a product mixture comprising the CBG or the CBG homolog. The method may further comprise separating the CBG or the CBG analog from the product mixture and may further comprise purifying the CBG or CBG analog. Methods for preparing cannabigerolic acid (CBGA) or a cannabigerolic acid analog are also disclosed. The present disclosure also provides highly purity CBG, CBGA, and analogs thereof.
    Type: Application
    Filed: March 21, 2022
    Publication date: September 8, 2022
    Applicant: Canopy Growth Corporation
    Inventors: Daniel BRUMAR, Mahmood Azizpour FARD, Ben GEILING, Mohammadmehdi HAGHDOOST MANJILI
  • METHODS OF SYNTHESIZING CANNABIGERGOL, CANNABIGEROLIC ACID, AND ANALOGS THEREOF
    Publication number: 20230039312
    Abstract: Disclosed are methods for preparing cannabigerol (CBG) or a CBG analog, embodiments of the method comprising providing a compound (I); combining the compound (I) with geraniol and a solvent to form a reaction mixture; and combining the reaction mixture with an acid catalyst to form a product mixture comprising the CBG or the CBG homolog. The method may further comprise separating the CBG or the CBG analog from the product mixture and may further comprise purifying the CBG or CBG analog. Methods for preparing cannabigerolic acid (CBGA) or a cannabigerolic acid analog are also disclosed. The present disclosure also provides highly purity CBG, CBGA, and analogs thereof.
    Type: Application
    Filed: August 8, 2022
    Publication date: February 9, 2023
    Applicant: Canopy Growth Corporation
    Inventors: Daniel BRUMAR, Mahmood Azizpour FARD, Ben GEILING, Mohammadmehdi HAGHDOOST MANJILI
  • Topical composition with active compounds from and for reduction of skin lesions
    Patent number: 11813301
    Abstract: Disclosed is a method of treatment using a topical composition including essential sombination of synergistically acting phyto-active materials, non-psychotropic phtocannabinoids from the plant of Cannabis sativa: Cannabidiol, Cannabidiolic acid, Cannabivarian Cannabigerol in combination with extract of Calendula flower and the formulation of the base to ensure the features of anti-inflammation, anti-oxidation, emollient, and bactericidal components. The topical composition is an emollient dedicated for reduction of skin lesions caused by atopic dermatitis, urticaria, radiotherapy and UV induced skin damage and acne. In addition, the topical composition could reduce secretion of fats, facilitate deep skin hydration, reduce pores, and exert soothing effects.
    Type: Grant
    Filed: May 27, 2022
    Date of Patent: November 14, 2023
    Assignee: UAB Satimed
    Inventors: Juozas Siurkus, Rimantas Peciura
  • THE TOPICAL COMPOSITION WITH ACTIVE COMPOUNDS FROM CANNABIS SATIVA AND CALENDULA OFFICINALIS FOR REDUCTION OF SKIN LESIONS
    Publication number: 20220296664
    Abstract: Disclosed is a method of treatment using a topical composition including essential sombination of synergistically acting phyto-active materials, non-psychotropic phtocannabinoids from the plant of Cannabis sativa: Cannabidiol, Cannabidiolic acid, Cannabivarian Cannabigerol in combination with extract of Calendula flower and the formulation of the base to ensure the features of anti-inflammation, anti-oxidation, emollient, and bactericidal components. The topical composition is an emollient dedicated for reduction of skin lesions caused by atopic dermatitis, urticaria, radiotherapy and UV induced skin damage and acne. In addition, the topical composition could reduce secretion of fats, facilitate deep skin hydration, reduce pores, and exert soothing effects.
    Type: Application
    Filed: May 27, 2022
    Publication date: September 22, 2022
    Inventors: Juozas SIURKUS, Rimantas PECIURA
  • Methods of synthesizing cannabigergol, cannabigerolic acid, and analogs thereof
    Patent number: 11643380
    Abstract: Disclosed are methods for preparing cannabigerol (CBG) or a CBG analog, embodiments of the method comprising providing a compound (I); combining the compound (I) with geraniol and a solvent to form a reaction mixture; and combining the reaction mixture with an acid catalyst to form a product mixture comprising the CBG or the CBG homolog. The method may further comprise separating the CBG or the CBG analog from the product mixture and may further comprise purifying the CBG or CBG analog. Methods for preparing cannabigerolic acid (CBGA) or a cannabigerolic acid analog are also disclosed. The present disclosure also provides highly purity CBG, CBGA, and analogs thereof.
    Type: Grant
    Filed: March 21, 2022
    Date of Patent: May 9, 2023
    Inventors: Daniel Brumar, Mahmood Azizpour Fard, Ben Geiling, Mohammadmehdi Haghdoost Manjili
  • Cannabinoid and Terpene-Infused Topical Cream
    Publication number: 20200197359
    Abstract: The present invention is a topical composition comprising terpene blend and a cannabinoid such as isolated tetrahydrocannabinol (THC), cannabidiol (CBD) and is useful for managing pain, the treatment or prevention of inflammatory skin disorders, and treatment methods thereof. The composition particularly includes a cream base including aloe extract, 1-10% on a weight to weight basis of the composition is a terpene blend selected from the group consisting of: alpha bisabolol, alpha pinene, delta-3-carene, beta caryophyllene, alpha humulene, terpinolene, nerolidol, camphene, linalool, limonene, myrcene, terpineol, beta pinene, ocimene, a pharmaceutically acceptable salt, ester or solvate thereof, or any combination thereof. The composition further includes glycerin, lecithin, propylene glycol, 2-pyrrolidone-5-carboxylic acid and 1-10% on a weight to weight basis of the composition is a first cannabinoid such as THC, CBD, or Cannabigerol (CBG).
    Type: Application
    Filed: February 7, 2020
    Publication date: June 25, 2020
    Inventors: Cody D. Freeze, Allison Freeze
  • PHYTOTERPENOID FACILITATION OF THERAPEUTIC ONSET AND EFFICACY OF SUBLINGUAL CANNABINOID ADMINISTRATION
    Publication number: 20180193304
    Abstract: A cannabis plant extract based formulation to aid in stabilizing the therapeutic efficacy of cannabinoid containing treatments in patients affected with neurological diseases that comprises one or more of the following: Cannabidiol (CBD), tetrahydrocannabinol (THC), and terpenes; wherein the formulation comprises a high ratio of CBD to THC, with each of those cannabinoids in a relatively high concentration. The formulation also comprises Beta-caryophyllene that is used to further aid in neuroprotection by co-modulating CB1 and 2 receptors. Additionally, the formulation comprises the terpene humulene to assist in creating an “entourage effect” in conjunction with CBD, THC, and Beta-caryophyllene to stabilize and enhance treatment-related pharmacological actions. The formulation may also comprise Cannabichromene (CBC), Cannabigerol (CBG), and Cannabinol (CBN).
    Type: Application
    Filed: January 10, 2018
    Publication date: July 12, 2018
    Applicant: JC Pharma Inc.
    Inventors: Jason Allen Cranford, Donald Channing Cooper
  • CANNABINOID-CONTAINING COMPLEX MIXTURES FOR THE TREATMENT OF MAST CELL-ASSOCIATED OR BASOPHIL-MEDIATED INFLAMMATORY DISORDERS
    Publication number: 20210212961
    Abstract: Provided herein are cannabinoid-containing complex mixtures suitable for use as active pharmaceutical ingredients. The complex mixtures are comprised of the major cannabinoid, cannabidiol, a first minor cannabinoid, which is cannabigerol, at least a first selected terpene, and optionally a second minor cannabinoid. Also provided are methods of making the complex mixtures, pharmaceutical compositions comprising the complex mixture, and methods of using the pharmaceutical compositions for the treatment of mast cell-related immune disorders, including allergy and atopy (allergic asthma, eczema, rhinitis), mast cell activation syndrome (MCAS), physical and chemical urticarias, idiopathic urticaria, Crohn's disease, inflammatory bowel disorder, dermatitis and contact dermatitis, arthritis and rheumatoid arthritis, canine mastocytosis, and allergy and inflammation in cattle, swine, etc. The methods of the present invention further relate to the treatment of various basophil-mediated immune disorders.
    Type: Application
    Filed: October 7, 2020
    Publication date: July 15, 2021
    Inventors: Andrea Small-Howard, Helen Turner
  • Alkylated resorcinol derivatives for the treatment of immune diseases
    Patent number: 6274635
    Abstract: The present invention provides a method, compounds, and compositions for treating a disease associated with immune dysfunction. In accordance with the method, a pharmacologically-acceptable composition including at least one compound selected from the group of compounds consisting of 5-alkyl-resorcinol derivatives, cannabinol derivatives, cannabidiol derivatives, cannabigerol derivatives, and combinations thereof is administered to a patient under conditions sufficient to attenuate the dysfunction within the immune system. The invention also provides an antiviral cannabinol derivative that can be used in the inventive method. The invention also provides an alkylated resorcinol derivative and a method of using the alkylated resorcinol derivative to attenuate the growth of a neoplasm. The method and compound are useful for treating diseases of the immune system, such as HIV disease and neoplastic disorders.
    Type: Grant
    Filed: March 22, 2000
    Date of Patent: August 14, 2001
    Assignee: Immugen Pharmaceuticals Inc.
    Inventor: Craig A. Travis
  • CANNABINOID-CONTAINING COMPLEX MIXTURES FOR THE TREATMENT OF MAST CELL-ASSOCIATED OR BASOPHIL-MEDIATED INFLAMMATORY DISORDERS
    Publication number: 20180221304
    Abstract: Provided herein are cannabinoid-containing complex mixtures suitable for use as active pharmaceutical ingredients. The complex mixtures are comprised of the major cannabinoid, cannabidiol, a first minor cannabinoid, which is cannabigerol, at least a first selected terpene, and optionally a second minor cannabinoid. Also provided are methods of making the complex mixtures, pharmaceutical compositions comprising the complex mixture, and methods of using the pharmaceutical compositions for the treatment of mast cell-related immune disorders, including allergy and atopy (allergic asthma, eczema, rhinitis), mast cell activation syndrome (MCAS), physical and chemical urticarias, idiopathic urticaria, Crohn's disease, inflammatory bowel disorder, dermatitis and contact dermatitis, arthritis and rheumatoid arthritis, canine mastocytosis, and allergy and inflammation in cattle, swine, etc. The methods of the present invention further relate to the treatment of various basophil-mediated immune disorders.
    Type: Application
    Filed: January 31, 2018
    Publication date: August 9, 2018
    Inventors: Andrea Small-Howard, Helen Turner
  • Cannabinoid-containing complex mixtures for the treatment of mast cell-associated or basophil-mediated inflammatory disorders
    Patent number: 10857107
    Abstract: Provided herein are cannabinoid-containing complex mixtures suitable for use as active pharmaceutical ingredients. The complex mixtures are comprised of the major cannabinoid, cannabidiol, a first minor cannabinoid, which is cannabigerol, at least a first selected terpene, and optionally a second minor cannabinoid. Also provided are methods of making the complex mixtures, pharmaceutical compositions comprising the complex mixture, and methods of using the pharmaceutical compositions for the treatment of mast cell-related immune disorders, including allergy and atopy (allergic asthma, eczema, rhinitis), mast cell activation syndrome (MCAS), physical and chemical urticarias, idiopathic urticaria, Crohn's disease, inflammatory bowel disorder, dermatitis and contact dermatitis, arthritis and rheumatoid arthritis, canine mastocytosis, and allergy and inflammation in cattle, swine, etc. The methods of the present invention further relate to the treatment of various basophil-mediated immune disorders.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: December 8, 2020
    Assignee: GBS Global BioPharma, Inc.
    Inventors: Andrea Small-Howard, Helen Turner
  • CANNABIGEROL (CBG) PRODUCTS AND METHODS OF USE
    Publication number: 20240082270
    Abstract: A pharmaceutically acceptable formulation comprising a cannabinoid, e.g., CBG, CBGA, CBGV, and CBGVA, or a pharmaceutically acceptable salt or ester thereof, substantially without CBDA synthase products and TCHA synthase products; and at least one additional active composition, e.g., an endocannabinoid, dextromethorphan, melatonin, 5-hydroxy tryptophan, or serotonin. The cannabinoid may be a full spectrum or broad spectrum extract of a plant of genus Cannabis, containing cannabinoids, terpenes, and flavonoids, and substantially without cannabidiol and tetrahydrocannabinol. The composition may be a pharmaceutically acceptable formulation for oral, mucosal (including sublingual), topical, inhaled, vaporized or spray, or smoked administration. The formulation may include absorption or pharmacological (synergistic) exogenous enhancers, e.g., curcumin, resveratrol, quercetin, piperine, butyrate (or its natural derivatives) and other (endo)cannabinoids.
    Type: Application
    Filed: November 20, 2023
    Publication date: March 14, 2024
    Inventors: Michael Elzufon, Howard Hoffberg
  • Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
    Patent number: 6949582
    Abstract: A method of relieving analgesia and reducing inflammation using a cannabinoid delivery topical liniment composition containing from about 97.5% to about 99.5% by weight a 70% monohydric alcohol solution, and from about 0.5% to about 2.5% by weight of a synergistic cannabinoid mixture extracted from the female plant Cannabis sativa L, including in combination: 9-Tetrahydrocannabinol (delta-9-THC), 9-THC Propyl Analogue (THC-V), Cannabidiol (CBD), Cannabidiol Propyl Analogue (CBD-V), Cannabinol (CBN), Cannabichromene (CBC), Cannabichromene Propyl Analogue (CBC-V), Cannabigerol (CBG), terpenoids, and flavonoids. The liniment is applied topically, preferably by spraying, and the constituents of the mixture are absorbed through the skin and interact with cannabinoid receptors in the body and tissues of a human patient to produce therapeutic analgesic and anti-inflammatory effects without undesirable psychotropic side effects.
    Type: Grant
    Filed: September 13, 2002
    Date of Patent: September 27, 2005
    Inventor: Walter H. Wallace
  • STABLE CANNABINOID COMPOSITIONS
    Publication number: 20210401746
    Abstract: The present application discloses powder and aqueous formulations. These include but are not limited to water dispersible cannabinoid formulations, especially those comprising cannabidiol (CBD), cannabigerol (CBG), and cannabinol (CBN) as well as other cannabinoids. Generally, these embodiments do not include major amounts of Tetrahydrocannabinol (THC), but certain embodiments are envisioned that do contain measurable concentrations of THC.
    Type: Application
    Filed: June 25, 2021
    Publication date: December 30, 2021
    Inventor: Justin D. Crumrine
  • Cannabinoid Composition and Method For Treating Pain
    Publication number: 20190030062
    Abstract: A combination of THC, CBD and Cobalamin (in a ratio of about 63%, 27% and 10%, respectively) is used with a topical carrier such as Shea butter cream to relieve pain. The THC and CBD mixture is extracted from a Cannabis Indica dominant strain using high pressure and carbon dioxide (CO2) as a solvent and comprises: Tetrahydrocannabinol “THC” (9-Tetrahydrocannabinol (delta-9 THC), 8-Tetrahydrocannabinol (Delta-8 THC) and 9-THC Acid), Cannabidiol “CBD”, Cannabinol “CBN”, Cannabichromene (“CBC), Cannabigerol (“CBG”), terpenoids and flavonoids. The Shea butter is an extract from the Shea nut from the Shea tree (Vitellaria paradoxa). The weight of THC, CBD and Cobalamin, excluding other ingredients in the Indica extract, is in the range of about 1.0% to 5% of the total weight of the Shea butter. The cream is applied to joints for indications such as Psoriatic Arthritis and Scleroderma.
    Type: Application
    Filed: October 1, 2018
    Publication date: January 31, 2019
    Applicant: India Globalization Capital, Inc.
    Inventors: Ramachandra MUKUNDA, Ranga Chelva KRISHNA
  • OLIVETOLIC ACID CYCLASE VARIANTS AND METHODS FOR THEIR USE
    Publication number: 20220315969
    Abstract: Described herein are olivetolic acid cyclases (OAC) including non-natural variants capable of forming a 2,4-dihydroxy-6-alkylbenzoic acid from a 3,5,7-trioxoacyl-CoA or a 3,5,7-trioxocarboxylate substrate. In some examples, the non-natural OAC is capable of forming a 2,4-dihydroxy-6-alkylbenzoic acid from a 3,5,7-trioxoacyl-CoA or a 3,5,7-trioxocarboxylate substrate at a greater rate. In some examples, the non-natural OAC has a higher affinity for a 3,5,7-trioxoacyl-CoA or a 3,5,7-trioxocarboxylate substrate, as compared to the wild type OAC. The non-natural OAC can be used with olivetol synthase (OLS) to form the 2,4-dihydroxy-6-alkylbenzoic acid from malonyl-CoA and acyl-CoA through to a 3,5,7-trioxoacyl-CoAintermediate. The non-natural OAC (and OLS) can be expressed in an engineered cell having a pathway to form cannabinoids, which include CBGA, its analogs and derivatives. CBGA can be used for the preparation of cannabigerol (CBG), which can be used in therapeutic compositions.
    Type: Application
    Filed: June 5, 2020
    Publication date: October 6, 2022
    Inventors: Michael Angus Noble, Russell Scott Komor
  • Cannabinoid composition and method for treating pain
    Patent number: 10933082
    Abstract: A combination of THC, CBD and Cobalamin (in a ratio of about 63%, 27% and 10%, respectively) is used with a topical carrier such as Shea butter cream to relieve pain. The THC and CBD mixture is extracted from a Cannabis indica dominant strain using high pressure and carbon dioxide (CO2) as a solvent and comprises: Tetrahydrocannabinol “THC” (9-Tetrahydrocannabinol (delta-9 THC), 8-Tetrahydrocannabinol (Delta-8 THC) and 9-THC Acid), Cannabidiol “CBD”, Cannabinol “CBN”, Cannabichromene (“CBC), Cannabigerol (“CBG”), terpenoids and flavonoids. The Shea butter is an extract from the Shea nut from the Shea tree (Vitellaria paradoxa). The weight of THC, CBD and Cobalamin, excluding other ingredients in the Indica extract, is in the range of about 1.0% to 5% of the total weight of the Shea butter. The cream is applied to joints for indications such as Psoriatic Arthritis and Scleroderma.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: March 2, 2021
    Assignee: India Globalization Capital, Inc.
    Inventors: Ramachandra Mukunda, Ranga Chelva Krishna
Narrow Results

Filter by US Classification